Genzyme joins the never-ending list of Ablynx’ partners

22/05/2015 - 2 minutes

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. 

Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple sclerosis research programs involving neuroprotection and central nervous system repair. The neurodegeneration observed in multiple sclerosis is not directly targeted by existing treatments and with the single-domains antibodies developed by Ablynx, Genzyme is expecting to answer a pressing medical need.

Under the terms of the agreement, Genzyme will have the right to perform in vitro and in vivo research with Ablynx’s Nanobodies in preclinical studies in return of an exclusivity fee. After completion of these studies, Genzyme will have the possibility to negotiate a license agreement. According to Ablynx, the Nanobodies have already shown promising results against the specific target of interest and confirmed their activity in pre-clinical models.

The Nanobody technology  platform aims at creating new single variable domain antibodies derived from the llama immune-system.  

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member